11. | What is the cost of, and capacity covered by, the manufacturing arrangement with International Isotopes? Why have you not publicly disclosed this arrangement? |
12. | How much will the MIP-1095 Phase 2 trial and AZEDRA basket trial cost? |
13. | Why has the Company neither refinanced the Relistor non-recourse debt nor borrowed further against this valuable royalty stream to provide accretion (vs. management's seeming preference for dilutive equity issuances)? |
